이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

비디오 후두경 검사 보조 기관 삽관 최적화를 위한 Remifentanil과 Rocuronium 비교 (ROCVIDEO)

2026년 9월 16일 업데이트: Nordsjaellands Hospital

전신 마취를 받는 환자의 비디오 후두경 검사 보조 기관 삽관 최적화를 위한 Remifentanil 대 Rocuronium - 다기관 무작위 대조 시험 - ROCVIDEO 시험

Globally, we are approaching 1 million surgical procedures each day. Tracheal intubation is the mainstay of securing the patient's airway and breathing during general anaesthesia. Approximately 100.000 tracheal intubations are performed annually in Denmark. Airway management remains the primary reason for anaesthesia-related morbidity and mortality. It has been traditionally accepted that best tracheal intubation conditions are obtained by paralysing the patient's muscles, including vocal cords, using a neuromuscular blocking agent (NMBA) such as rocuronium. However, using NBMA may increase the risk of pulmonary complications, intra-operative awareness, in which the patient is paralysed but awake during surgery, anaphylaxis, and re-intubation. In addition, there is a risk of residual neuromuscular blockade postoperatively. In the US, prolonged ventilation and unplanned intubation are the top two most costly perioperative complications. An alternative to NMBA is a large dose of opioids to depress laryngeal reflexes during intubation. The most commonly used non-NMBA modality includes bolus administration of remifentanil. However, remifentanil may cause bradycardia and hypotension. Even short periods of hypotension have been shown to increase the risk of myocardial injury and other serious adverse events such as renal failure, delirium, and even mortality.

Evidence also indicates that intubation conditions using only opioids to facilitate intubation, including remifentanil, are inferior to NMBA. However, these trials are underpowered to assess effects on patient-important outcomes and are mostly at high risk of bias. A recent trial has suggested that remifentanil intubation conditions may not be very different. Almost all existing research comparing NMBA to opioids has focused on intubation conditions for direct laryngoscopy using a conventional Macintosh laryngoscopy blade. In recent years, the implementation and availability of the video laryngoscope have grown exponentially and become universal. The video laryngoscope has vastly improved the ease of tracheal intubation, and the number of failed intubations has decreased by two-thirds in Denmark, where a rapid implementation of the video laryngoscope took place. However, limited evidence exists on whether NMBA improves intubation conditions compared to remifentanil when performing video laryngoscope-assisted tracheal intubation.

연구 개요

연구 유형

중재적

등록 (추정된)

2684

단계

  • 4단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 연락처 백업

연구 장소

      • Copenhagen, 덴마크, 2100
        • 모병
        • Department of Anesthesiology, NOH, Rigshospitalet
        • 연락하다:
      • Hillerød, 덴마크, 3400

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Adults ≥ 18 years
  • Undergoing general anaesthesia requiring oro-tracheal intubation
  • Absence of indication for rapid sequence induction
  • American Society of Anesthesiologists (ASA) physical status score I - III

Exclusion Criteria:

  • Known allergies or contraindications to rocuronium (e.g. neuromuscular disease) or remifentanil
  • Awake intubation
  • Double-lumen endotracheal tube
  • Oral, pharyngeal, and laryngeal surgery
  • Surgical contraindication for NMBAs (e.g. use of nerve stimulator)
  • Patients who are pregnant or breastfeeding
  • Patients who do not understand Danish or are unable to give informed consent

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 네 배로

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: REMI-arm

Bolus of remifentanil at anaesthesia induction

Age < 70 years: Bolus of 4 μg/kg Ideal Body Weight remifentanil at anaesthesia induction; Age >= 70 years: Bolus of 2 μg/kg ideal Body Weight remifentanil at anaesthesia induction

다른 이름들:
  • 레미펜타닐 5mg을 식염수 100ml에 희석하여, 이는 레미펜타닐 50 마이크로그램/ml에 해당합니다.
활성 비교기: ROCU-arm

Bolus of rocuronium at anaesthesia induction

Bolus of 0.6 mg/kg Ideal Body Weight rocuronium at anaesthesia induction

다른 이름들:
  • 로쿠로늄 10mg/ml

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Proportion of participants with one or more intubation or anaesthesia related adverse events
기간: 0 minutes to 24 hours after administration of drugs for intubation

Early (< 10 min): Cardiac arrest; anaphylaxis; pulmonary aspiration of gastric content; serious traumatic airway injury; desaturation (SAT < 90%); major hemodynamic instability (MAP < 50, new onset bradycardia < 40 beats/min); or sustained new arrhythmia (causing hemodynamic instability or requiring intervention).

Late (< 24 h): Death; brain damage including stroke; acute myocardial infarction; ICU admission; re-intubation; respiratory failure (oxygen demand > 5 l/min or requiring interventions aside from oxygen therapy); intraoperative awareness; pneumonia; dental injury; sore throat; or hoarseness.

0 minutes to 24 hours after administration of drugs for intubation
Proportion of participants with failed first-pass intubation
기간: Tracheal intubation is performed 2 minutes after administration of rocuronium or remifentanil.

Defined as failed tracheal tube delivery after the first attempt of introduction of the video laryngoscope into the patient's mouth.

Tracheal tube delivery is defined as failed when the tube is retracted out of the patient's mouth, OR the video laryngoscope has to be retracted out of the patient's mouth, OR there is a shift in intubation equipment OR a change in the person performing the intubation management OR the intubation is abandoned.

Tracheal intubation is performed 2 minutes after administration of rocuronium or remifentanil.

2차 결과 측정

결과 측정
측정값 설명
기간
Patient satisfaction score
기간: 24 hours after administration of drugs for intubation

The patient's experience of the treatment using a numeric rating scale (NRS 0 - 10 (0 = very dissatisfied; 10 = very satisfied))

24 hours after administration of drugs for intubation
Proportion of participants with one or more serious adverse events 0-7 days
기간: 0 minutes to 7 days after administration of drugs for intubation

Defined as: respiratory failure, major adverse cardiac (in-hospital all-cause death, acute myocardial infarction (AMI) both acute ST elevation MI and non-ST elevation MI, complete heart block, cardiogenic shock, cardiac arrhythmia and cardiac arrest), pneumonia, acute kidney injury, admission to ICU and cerebrovascular event (ischemic stroke including transient cerebral ischemia).

0 minutes to 7 days after administration of drugs for intubation
Lengths of stay at the Post-Anaesthesia Care Unit.
기간: 0-48 hours postoperatively

Minutes the patient is at the Post-Anaesthesia Care Unit.

0-48 hours postoperatively

기타 결과 측정

결과 측정
측정값 설명
기간
Proportion of participants with failed intubation
기간: 2 to 20 minutes after administration of drugs for intubation

The intubation is abandoned

2 to 20 minutes after administration of drugs for intubation
Number of intubation attempts
기간: 2 to 20 minutes after administration of drugs for intubation

The first attempt is defined as an attempt (successful or not) at tracheal tube delivery after the first introduction of the video laryngoscope into the patient's mouth.

Additionally attempts are defined as: when the tube has to be re-introduced into the patient's mouth, OR the videolaryngoscopy has to be re-introduced into the patient mouth, OR there is a shift in intubation equipment OR a change in the person performing the intubation management

2 to 20 minutes after administration of drugs for intubation
Vocal cords position at first intubation attempt
기간: 2 to 20 minutes after administration of drugs for intubation

Categorised as closed, intermediate or open

2 to 20 minutes after administration of drugs for intubation
Proportion of participants with need for rescue medication or airway management
기간: 2 to 20 minutes after administration of drugs for intubation

Rescue medication is defined as: An additional bolus of neuromuscular blocking agents, or bolus of opioid or propofol or other anesthetics according to the discretion of the attending anaesthesiologist in order to solve insufficient airway management conditions.

2 to 20 minutes after administration of drugs for intubation
Proportion of participants with anaesthesia induction related grave desaturation
기간: 0 to 10 minutes after administration of drugs for intubation

SAT < 80%

0 to 10 minutes after administration of drugs for intubation
Proportion of participants in need of vasoactive or chronotropic substances after induction
기간: 0 to 10 minutes after administration of drugs for intubation

Defined as any vasoactive substance, e.g. epinephrine, noradrenaline, phenylephrine, ephedrine administrated as a response to severe hypotension or bradycardia after induction.

0 to 10 minutes after administration of drugs for intubation
Individual components of the composite outcomes "Proportion of participants with one or more intubation or anaesthesia related adverse events" and "Proportion of participants with one or more serious adverse events 0-7 days"
기간: 0 minutes to 7 days after administration of drugs for intubation

As stated in the relevant outcome descriptions

0 minutes to 7 days after administration of drugs for intubation

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Anders K Nørskov, PhD, Department of Anaesthesia, Nordsjællands Hospital - Hillerød, Denmark
  • 수석 연구원: Matias Vested, PhD, Department of Anaesthesia Centre of Head and Orthopedics Rigshospitalet, University of Copenhagen

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2025년 11월 17일

기본 완료 (추정된)

2027년 4월 1일

연구 완료 (추정된)

2027년 4월 8일

연구 등록 날짜

최초 제출

2024년 6월 25일

QC 기준을 충족하는 최초 제출

2024년 8월 19일

처음 게시됨 (실제)

2024년 8월 21일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 9월 21일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 16일

마지막으로 확인됨

2025년 10월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

Anonymised data will be made available upon reasonable request

IPD 공유 기간

The protocol is submitted prior to first randomisation. A comprehensive statistical analysis plan, including pre-specified subgroup analysis will be published before the final participant is enrolled.

Other material will be made available <12 months after trial cessation

IPD 공유 액세스 기준

Anonymised data will be made available upon reasonable request.

IPD 공유 지원 정보 유형

  • 연구_프로토콜
  • 수액
  • ICF
  • ANALYTIC_CODE
  • CSR

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다